A phase IIa multi-dose study in cirrhotic patients using a tablet formulation to determine the steady-state pharmacokinetics and pharmacodynamics of OCR-002

Trial Profile

A phase IIa multi-dose study in cirrhotic patients using a tablet formulation to determine the steady-state pharmacokinetics and pharmacodynamics of OCR-002

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Ornithine phenylacetate (Primary)
  • Indications Hepatic encephalopathy
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 23 Aug 2017 According to an Ocera Therapeutics media release, results from this study are expected to be published by the end of 2017.
    • 01 Jun 2017 According to an Ocera Therapeutics media release, the first patient has been dosed in this trial.
    • 01 Jun 2017 According to an Ocera Therapeutics media release, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top